Search details
1.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Oncologist
; 28(10): 845-855, 2023 10 03.
Article
in English
| MEDLINE | ID: mdl-37318349
2.
Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
Breast Cancer Res Treat
; 197(1): 51-56, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-36318381
3.
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Breast Cancer Res Treat
; 202(1): 191-201, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37589839
4.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw
; 21(6): 594-608, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37308117
5.
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(6): 691-722, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35714673
6.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Article
in English
| MEDLINE | ID: mdl-32966830
7.
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.
J Natl Compr Canc Netw
; 19(5): 484-493, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-34794122
8.
Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer.
Circulation
; 139(21): 2451-2465, 2019 05 21.
Article
in English
| MEDLINE | ID: mdl-30866650
9.
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 18(4): 452-478, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32259783
10.
Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Proc Natl Acad Sci U S A
; 114(52): 13792-13797, 2017 12 26.
Article
in English
| MEDLINE | ID: mdl-29229854
11.
NCCN Guidelines Updates: Breast Cancer.
J Natl Compr Canc Netw
; 17(5.5): 552-555, 2019 05 01.
Article
in English
| MEDLINE | ID: mdl-31117035
12.
NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
J Natl Compr Canc Netw
; 17(2): 118-126, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30787125
13.
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Breast Cancer Res Treat
; 168(3): 625-630, 2018 Apr.
Article
in English
| MEDLINE | ID: mdl-29275435
14.
Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
J Natl Compr Canc Netw
; 16(7): 845-850, 2018 07.
Article
in English
| MEDLINE | ID: mdl-30006427
15.
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 16(3): 310-320, 2018 Mar.
Article
in English
| MEDLINE | ID: mdl-29523670
16.
NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
J Natl Compr Canc Netw
; 15(4): 433-451, 2017 04.
Article
in English
| MEDLINE | ID: mdl-28404755
17.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Future Oncol
; 13(4): 307-320, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27739325
18.
Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Ann Surg Oncol
; 23(10): 3310-6, 2016 10.
Article
in English
| MEDLINE | ID: mdl-27401442
19.
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 14(3): 324-54, 2016 Mar.
Article
in English
| MEDLINE | ID: mdl-26957618
20.
BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
Lancet Oncol
; 21(10): 1254-1255, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32861274